

Special Issue

Chikungunya Virus and (Re-) Emerging Alphaviruses

Message from the Guest Editors

Since 2003, the “Old World” chikungunya virus has re-emerged and spread throughout the world in more than 40 countries, posing a big threat to public health. This mosquito-borne virus, belonging to the genus of *Alphavirus* in the family of *Togaviridae*, causes acute infection with symptoms ranging from fever, rash, myalgia, to severe arthralgia and arthritis. Although with a low fatality rate, this virus can produce chronic infection, characterized by muscle and joint pain which afflicts patients for months to years and has a substantial impact on their quality of life. Additionally, the (re-) emergence of other members of the genus *Alphavirus* that cause severe diseases in animals and/or humans has raised great concerns. Therefore, an overview of alphavirus research is timely and will greatly help the control and prevention of viral disease transmission. In this Special Issue, we welcome the alphavirus community to submit research articles or review papers related to all aspects of chikungunya virus and other (re-) emerging alphaviruses.

Guest Editors

Dr. Penghua Wang

Department of Immunology, School of Medicine, the University of Connecticut Health Center, Farmington, CT, USA

Dr. Rong Zhang

Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA

Deadline for manuscript submissions

closed (28 February 2019)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/18355

Viruses
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

Director, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2024).